"Valproic acid shown to halt vision loss in patients with retinitis pigmentosa" http://www.eurekalert.org/pub_releases/2010-07/uomm-vas072110.php Contact: Jim Fessenden james.fessenden@xxxxxxxxxxxx 508-856-2000 University of Massachusetts Medical School Valproic acid shown to halt vision loss in patients with retinitis pigmentosa UMass Medical School coordinating a $2.1 million three-year clinical trial WORCESTER, MASS. - Researchers at the University of Massachusetts Medical School (UMMS) believe they may have found a new treatment for retinitis pigmentosa (RP), a severe neurodegenerative disease of the retina that ultimately results in blindness. One of the more common retinal degenerative diseases, RP is caused by the death of photoreceptor cells and affects 1 in 4,000 people in the United States. RP typically manifests in young adulthood as night blindness or a loss of peripheral vision and in many cases progresses to legal blindness by age 40. In the July 20 online edition of the British Journal of Ophthalmology, Shalesh Kaushal, MD, PhD, chair of ophthalmology and associate professor of ophthalmology and cell biology at UMMS, and his team, describe a potential new therapeutic link between valproic acid and RP, which could have tremendous benefits for patients suffering from the disease. In a retrospective study, valproic acid-approved by the FDA to reduce seizures, treat migraines and manage bipolar disorder-appeared to have an effect in halting vision loss in patients with RP and in many cases resulted in an improved field of vision. Results from this study, in conjunction with prior in vitro data, suggest valproic acid may be an effective treatment for photoreceptor loss associated with RP. UMass Medical School will be the coordinating site for a $2.1 million, three-year clinical trial funded by the Foundation Fighting Blindness/National Neurovision Research Institute quantifying the potential of valproic acid as a treatment for RP. The clinical trials will build upon Kaushal's work in the retrospective study in which patients were treated off-label with doses of valproic acid ranging from 500mg to 750mg per day over the course of two to six months. Treated at a time when patients normally experience rapid vision loss as a result of RP, five of the seven patients in the study experienced improvement in their field of vision. "Inflammation and cell death are key components of RP," said Kaushal. "It appears the valproic acid protects photoreceptor cells from this. If our observations can be further substantiated by randomized clinical trials then low dose valproic acid could have tremendous potential to help the thousands of people suffering from RP." To date, discovery of a treatment for RP has been complicated by the fact that more than 40 different genes have been linked to the disease, making many interventions impractical or impossible; as a result, the disease remains largely untreated for an estimated 100,000 patients in the U.S. Most RP therapies currently being investigated focus on nutritional supplementation, vitamin A supplementation, light reduction or gene therapy. Dr. Kaushal and colleagues, having previously demonstrated the use of the small molecule, retinoid, as a pharmacological agent capable of increasing the yield of properly folded RP rhodopsins, began screening other small molecules for similar attributes. Because of its already known qualities as a potent inhibitor of the inflammatory response pathway and cell death, valproic acid was believed to have a unique profile making it a potential candidate as a retinal disease treatment. "Traditionally, moving a new scientific discovery from the bench to the patient requires a significant investment of time and resources," said Kaushal. "Repurposing drugs already approved by the FDA and which have been shown to be safe, such as valproic acid, is an economical and time-efficient way to quickly bring new treatments to patients." "The Foundation Fighting Blindness is delighted to be moving Dr. Kaushal's outstanding work with valproic acid into our clinical trial network, because the drug has the potential to preserve vision for thousands of people affected by retinal diseases," said Steve Bramer, Ph.D., chief drug development officer, National Neurovision Research Institute, a clinical support arm of the Foundation Fighting Blindness. "It's an exciting research collaboration for us, because of the drug's potential, and the knowledge and expertise Dr. Kaushal and the University of Massachusetts Medical School bring to the clinical study." ### About the University of Massachusetts Medical School The University of Massachusetts Medical School, one of the fastest growing academic health centers in the country, has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. The Medical School attracts more than $240 million in research funding annually, 80 percent of which comes from federal funding sources. The mission of the Medical School is to advance the health and well-being of the people of the commonwealth and the world through pioneering education, research, public service and health care delivery with its clinical partner, UMass Memorial Health Care. For more information, visit www.umassmed.edu . IN Partners In Policymaking: Here is a second abstract that was received about this. http://bjo.bmj.com/content/early/2010/07/20/bjo.2009.175356.abstract?sid=258 78fc8-046a-45e9-98e9-100777efaf17 Br J Ophthalmol doi:10.1136/bjo.2009.175356 Clinical science Therapeutic potential of valproic acid for retinitis pigmentosa Correspondence to Dr Shalesh Kaushal, Department of Ophthalmology, University of Massachusetts Medical School, 381 Plantation St., Biotech 5, Suite 250, Worcester, MA 01605; shalesh.kaushal@xxxxxxxxxxxxxxxxxx Contributors C M Clemson and R Tzekov contributed equally to this work. Accepted 6 March 2010 Published Online First 20 July 2010 Abstract Background/aim To examine the efficacy and safety of valproic acid (VPA) in patients with retinitis pigmentosa (RP). Methods Thirteen eyes were examined before and after brief treatment (average 4 months) with VPA. Visual fields (VF) for each eye were defined using digitised Goldmann Kinetic Perimetry tracings. VF areas were log-transformed and VF loss/gain relative to baseline was calculated. Visual acuity was measured using a Snellen chart at a distance of 20 feet (6.1 m). Values were converted to the logarithm of the minimum angle of resolution (logMAR) score. Results Nine eyes had improved VF with treatment, two eyes had decreased VF and two eyes experienced no change, with an overall average increase of 11%. Assuming typical loss in VF area without treatment, this increase in VF was statistically significant (p<0.02). An average decrease (0.172) in the logMAR scores was seen in these 13 eyes, which translates to a positive change in Snellen score of approximately 20/47 to 20/32, which was significant (p<0.02) assuming no loss in acuity without treatment. Side effects were mild and well tolerated. Conclusion Treatment with VPA is suggestive of a therapeutic benefit to patients with RP. A placebo-controlled clinical trial will be necessary to assess the efficacy and safety of VPA for RP rigorously. Check out the TABI resource web page at http://acorange.home.comcast.net/TABI and please make suggestions for new material. if you'd like to unsubscribe you can do so through the freelists.org web interface, or by sending an email to the address tabi-request@xxxxxxxxxxxxx with the word "unsubscribe" in the subject.